Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Chronic viral hepatitis is a global public health problem, with approximately 570 million persons chronically infected. Hepatitis B and C viruses increase the risk of morbidity and mortality from liver cirrhosis, hepatocellular carcinoma (HCC), and extrahepatic complications that develop. Hepatitis virus infection induces transforming growth factor (TGF)-β, which influences microenvironments within the infected liver. TGF-β promotes liver fibrosis by up-regulating extracellular matrix production by hepatic stellate cells. TGF-β is also up-regulated in patients with HCC, in whom it contributes importantly to bringing about a favorable microenvironment for tumor growth. Thus, TGF-β is thought to be a major factor regulating liver fibrosis and carcinogenesis. Since TGF-β carries out regulatory signaling by influencing the phosphorylation of Smads, we have generated several kinds of phospho-specific antibodies to Smad2/3. Using these, we have identified three types of phospohorylated forms: COOH-terminally phosphorylated Smad2/3 (pSmad2C and pSmad3C), linker phosphorylated Smad2/3 (pSmad2L and pSmad3L), and dually phosphorylated Smad3 (pSmad2L/C and pSmad3L/C). TGF-β-mediated pSmad2/3C signaling terminates cell proliferation; on the other hand, cytokine-induced pSmad3L signaling accelerates cell proliferation and promotes fibrogenesis. This review addresses TGF-β/Smad signal transduction in chronic liver injuries and carcinogenic processes. We also discuss the reversibility of Smad signaling after antiviral therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Zhou, B. P., Deng, J., Xia, W., Xu, J., Li, Y. M., Gunduz, M., & Hung, M.-C. (2004) · Nature Cell Biology · doi:10.1038/ncb1173 · Cited by 1,581 · cited 3×
“The down-regulation of E-cadherin has been shown to play an important role in the acquisition of metastatic capability by HCC. Increasing evidence suggests that chronic TGF-β stimulation promotes EMT as well as cancer stem cell properties and a higher invasive capability in HCC [128,129].”
BackgroundSpecific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934 · cited 1×
“Cyclin D knockout mice are protected from Ras-induced cancers [50].”
BackgroundNuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719 · cited 2×
“First, the TP site of Smad2 (Thr-220) and Smad3 (Thr-179) are almost the same.”
BackgroundTGF-β in progression of liver disease
Dooley, S., & ten Dijke, P. (2012) · Cell and Tissue Research · doi:10.1007/s00441-011-1246-y · Cited by 718
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539
Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition
Kluwe, J., Pradere, J., Gwak, G., Mencin, A., De Minicis, S., Österreicher, C. H., Colmenero, J., Bataller, R., & Schwabe, R. F. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.015 · Cited by 217
Smad3 phosphorylation by cyclin-dependent kinases
LIU, F. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.010 · Cited by 71
Cited by
TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019
Dewidar, B., Meyer, C., Dooley, S., & Meindl-Beinker, A. N. (2019) · Cells · doi:10.3390/cells8111419 · Cited by 837
Wu, Q., Zhou, L., Lv, D., Zhu, X., & Tang, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0739-0 · Cited by 281
Transforming Growth Factor-Beta (TGF-β) Signaling in Cancer-A Betrayal Within
Baba, A. B., Rah, B., Bhat, G. R., Mushtaq, I., Parveen, S., Hassan, R., Hameed Zargar, M., & Afroze, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.791272 · Cited by 224
“In addition, TGF-β inhibits DNA-binding protein inhibitor (ID1, 2, 3) and nuclear factors which plays a crucial role in cell differentiation and progression from G1 to S phase of cell cycle (Katz et al., 2013; Yoshida et al., 2018).”
BackgroundMesenchymal stem cell homing to improve therapeutic efficacy in liver disease
Yuan, M., Hu, X., Yao, L., Jiang, Y., & Li, L. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02858-4 · Cited by 89
Shi, Q., Xia, Y., Wu, M., Pan, Y., Wu, S., Lin, J., Kong, Y., Yu, Z., Zan, X., Liu, P., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.100958 · Cited by 14
“However, this route often results in the retention of MSCs in the lungs, where they are quickly eliminated by the immune system [15].”
Background
Metadata
- Authors
- Yoshida, K., Matsuzaki, K., Murata, M., Yamaguchi, T., Suwa, K., & Okazaki, K.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2018-06-05
- Volume
- 10
- Issue
- 6
- Pages
- 183
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2805876899
- Cited by
- 73
- References
- 8
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.